Optometrists in Crownpoint, NM Accepting Medicare
4 Optometrists found. Showing 1 - 4
 Dr. Roger William Studd, OD, MPH Optometrist Medicare: Medicare Enrolled Practice Location: Highway Junction 57, Route 9, Crownpoint, NM 87313 Phone: 505-786-5291 |
 Dr. Nazret Gaim Weldeghiorgis, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: Highway Junction 57, Route 9, Crownpoint, NM 87313 Phone: 505-786-5291 |
Karen Mai Linh Tong, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: Highway Junction 57, Route 9, Crownpoint, NM 87313 Phone: 505-786-6249 Fax: 505-786-6440 |
Tiffani Jackson, OD Optometrist Medicare: Medicare Enrolled Practice Location: Highway Junction 57, Route 9, Crownpoint, NM 87313 Phone: 505-786-2593 |
News Archive
Energy, sports drinks cause irreversible damage to enamel in adolescents
A recent study published in the May/June 2012 issue of General Dentistry, the peer-reviewed clinical journal of the Academy of General Dentistry, found that an alarming increase in the consumption of sports and energy drinks, especially among adolescents, is causing irreversible damage to teeth-specifically, the high acidity levels in the drinks erode tooth enamel, the glossy outer layer of the tooth.
Cherry-flavoured e-cigarette users may be exposed to potentially harmful chemical
An analysis of 145 different electronic-cigarette flavoring products reveals that many e-cigarette users may be exposed to a potentially harmful chemical. In a research letter published online today in the peer-reviewed journal Thorax, a research team led by Maciej Goniewicz, PhD, PharmD, of Roswell Park Cancer Institute reports that high levels of the respiratory irritant benzaldehyde were detected in the vapor from most of the flavored nicotine products they studied, with the highest concentrations in vapor from cherry-flavored products.
Novavax reports positive preclinical results for H1N1 influenza VLP vaccine
Novavax, Inc. (Nasdaq: NVAX) announced positive preclinical results with Novavax's 2009 novel H1N1 influenza virus-like particle (VLP) vaccine. The study, conducted by scientists from Novavax and the Centers for Disease Control and Prevention (CDC) based in Atlanta, GA, under a collaborative agreement, represents the first efficacy report of a 2009 novel H1N1 vaccine in ferrets. The ferret model is widely accepted to be the most appropriate animal model for evaluating influenza disease and vaccines. Novavax scientists designed the vaccine using recombinant virus like particles (VLP) technology against an H1N1 virus strain (A/California/04/2009) isolated in the beginning of the 2009 H1N1 outbreak.
Factors increasing risk for pertussis in children evaluated
Research shows that children with pertussis infection are significantly less likely to have had all five diphtheria, tetanus, and acellular pertussis vaccine doses than uninfected children.
› Verified 9 days ago